compname posts q2 fiscal 2021 fiscal year- 2021 results.
q1 revenue rose $384 million to $384 mln.
compname posts q4 2021 revenue $294 million, including $90 million of contract revenue.
qtrly product related revenue of $294 million, up 43% over year ago.
q1 revenue $251 million versus refinitiv ibes estimate of $262.8 million.
qtrly results benefited from covid-19 growth in qtrly adj. sales; qtr has no material impact of covid; ipo growth was expected to be lower than qtrlly.
compname reports record quarter 2020 results, with a $90 million contract revenue; up 30 percent.
q1 royalties $29 million versus refinitiv ibes estimate of $23.8 million.
compname reports q1 2021 results.
q1 non-gaap earnings per share $0.61; sees q3 2021 adjusted earnings per diluted share $1.21.
compname says has decided to take a very conservative approach to taking into consideration remaining baricitinib approval and development milestones for remainder of fiscal year.
revised initial $130 million financial guidance to end of full year.
now believes that this is still a very fluid situation, and we will update our long term guidance at appropriate times.
qtrly net foreign currency translation from cost accounting was approximately 15%.
compname announces q1 gross to net adjustments of 20%, as with similar oral oncology products.
compname says expect gross-to-net adjustment for full-year 2017 to be approximately 13% of sales.
